Off-label use of rituximab in dermatology: pemphigus treatment

Off-label use of rituximab in dermatology: pemphigus treatment

Since its approval in 1997 by the FDA (United States Food and Drug Administration), rituximab has been used for certain B-cell lymphomas and treatment-resistant rheumatoid arthritis. Nevertheless, over the past 14 years, many case reports have demonstrated the efficacy of off-label rituximab in several dermatological inflammatory conditions. This study describes two cases of pemphigus vulgaris and two cases of pemphigus foliaceous that were treated with rituximab at 375 mg/m2 once a week for 4 weeks, and that responded well to treatment.

Saved in:
Bibliographic Details
Main Authors: Bomm,Lislaine, Fracaroli,Tainá Scalfoni, Sodré,João Luz, Bressan,Aline, Gripp,Alexandre Carlos
Format: Digital revista
Language:English
Published: Sociedade Brasileira de Dermatologia 2013
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962013000400676
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S0365-05962013000400676
record_format ojs
spelling oai:scielo:S0365-059620130004006762015-10-19Off-label use of rituximab in dermatology: pemphigus treatmentBomm,LislaineFracaroli,Tainá ScalfoniSodré,João LuzBressan,AlineGripp,Alexandre Carlos biological treatment immunosuppressive agents pemphigus Since its approval in 1997 by the FDA (United States Food and Drug Administration), rituximab has been used for certain B-cell lymphomas and treatment-resistant rheumatoid arthritis. Nevertheless, over the past 14 years, many case reports have demonstrated the efficacy of off-label rituximab in several dermatological inflammatory conditions. This study describes two cases of pemphigus vulgaris and two cases of pemphigus foliaceous that were treated with rituximab at 375 mg/m2 once a week for 4 weeks, and that responded well to treatment.info:eu-repo/semantics/openAccessSociedade Brasileira de DermatologiaAnais Brasileiros de Dermatologia v.88 n.4 20132013-08-01info:eu-repo/semantics/othertext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962013000400676en10.1590/abd1806-4841.20131905
institution SCIELO
collection OJS
country Brasil
countrycode BR
component Revista
access En linea
databasecode rev-scielo-br
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author Bomm,Lislaine
Fracaroli,Tainá Scalfoni
Sodré,João Luz
Bressan,Aline
Gripp,Alexandre Carlos
spellingShingle Bomm,Lislaine
Fracaroli,Tainá Scalfoni
Sodré,João Luz
Bressan,Aline
Gripp,Alexandre Carlos
Off-label use of rituximab in dermatology: pemphigus treatment
author_facet Bomm,Lislaine
Fracaroli,Tainá Scalfoni
Sodré,João Luz
Bressan,Aline
Gripp,Alexandre Carlos
author_sort Bomm,Lislaine
title Off-label use of rituximab in dermatology: pemphigus treatment
title_short Off-label use of rituximab in dermatology: pemphigus treatment
title_full Off-label use of rituximab in dermatology: pemphigus treatment
title_fullStr Off-label use of rituximab in dermatology: pemphigus treatment
title_full_unstemmed Off-label use of rituximab in dermatology: pemphigus treatment
title_sort off-label use of rituximab in dermatology: pemphigus treatment
description Since its approval in 1997 by the FDA (United States Food and Drug Administration), rituximab has been used for certain B-cell lymphomas and treatment-resistant rheumatoid arthritis. Nevertheless, over the past 14 years, many case reports have demonstrated the efficacy of off-label rituximab in several dermatological inflammatory conditions. This study describes two cases of pemphigus vulgaris and two cases of pemphigus foliaceous that were treated with rituximab at 375 mg/m2 once a week for 4 weeks, and that responded well to treatment.
publisher Sociedade Brasileira de Dermatologia
publishDate 2013
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962013000400676
work_keys_str_mv AT bommlislaine offlabeluseofrituximabindermatologypemphigustreatment
AT fracarolitainascalfoni offlabeluseofrituximabindermatologypemphigustreatment
AT sodrejoaoluz offlabeluseofrituximabindermatologypemphigustreatment
AT bressanaline offlabeluseofrituximabindermatologypemphigustreatment
AT grippalexandrecarlos offlabeluseofrituximabindermatologypemphigustreatment
_version_ 1756412444120449024

Similar Items